50551-56-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxybenzofuran-2-carboxylic acid, ethyl ester is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
5-METHOXYBENZOFURAN-2-CARBOXYLIC ACID, ETHYL ESTER is also utilized as a precursor in the production of agrochemicals, playing a role in the creation of substances that can protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
5-Methoxybenzofuran-2-carboxylic acid, ethyl ester is employed as a precursor for the preparation of other organic compounds, facilitating the synthesis of a wide range of chemical entities for various applications.
Used in Therapeutic Research:
5-METHOXYBENZOFURAN-2-CARBOXYLIC ACID, ETHYL ESTER is used as a subject of research for its potential therapeutic uses, including the treatment of neurological disorders and as an anti-inflammatory agent, indicating its importance in the field of medicinal chemistry.
Used in Environmental and Health Risk Assessment:
5-Methoxybenzofuran-2-carboxylic acid, ethyl ester is considered in risk assessment studies to understand its potential impact on human health and the environment, ensuring the safe application of 5-METHOXYBENZOFURAN-2-CARBOXYLIC ACID, ETHYL ESTER in various industries.

InChI:InChI=1/C12H12O4/c1-3-15-12(13)11-7-8-6-9(14-2)4-5-10(8)16-11/h4-7H,3H2,1-2H3

Upstream product

• 76322-07-1 2-ethoxycarbonylmethoxy-5-methoxybenzaldehyde 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 685-87-0 Diethyl 2-bromomalonate 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 
• 64-17-5 ethanol 
• 1378942-37-0 C₉H₈Br₂O₂ 
• 13939-06-5 molybdenum hexacarbonyl 

Downstream Products

• 10242-08-7 5-methoxybenzofuran-2-carboxylic acid 
• 946851-73-6 C₂₁H₂₂O₅ 
• 463927-50-6 C₂₁H₂₀O₅Br₂ 
• 463927-52-8 C₁₈H₁₄O₅Br₂ 
• 463927-67-5 C₁₈H₁₄O₅Br₂ 
• 463927-68-6 C₂₅H₁₇O₆Br₂F 
• 463927-70-0 C₂₂H₁₁O₆Br₂F 
• 463927-51-7 C₂₀H₁₈O₅Br₂ 
• 463927-69-7 C₂₄H₁₅O₆Br₂F 
• 853599-45-8 5-(benzyloxy)benzo[b]furan-2-carboxylic acid ethyl ester 
• 859178-98-6 5-(benzyloxy)benzo[b]furan-2-carboxylic acid 
• 929897-10-9 5-(benzyloxy)benzo[b]furan-2-carbonyl chloride 
• 929897-12-1 [5-(benzyloxy)benzo[b]furan-2-yl][5-(benzyloxy)-1-(phenylsulfonyl)-1H-indol-2-yl]methanone 
• 929897-14-3 [5-(benzyloxy)benzo[b]furan-2-yl][5-(benzyloxy)-1H-indol-2-yl]methanone 

Relevant academic research and scientific papers

alpha-SYNUCLEIN AGGREGATE BINDING AGENT AND IMAGING METHOD

The present invention provides an α-synuclein aggregate binding agent that has high binding selectivity for an α-synuclein aggregate. The α-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii): R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.

BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and, thus, a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers. To this end, the present invention provides a compound represented by chemical formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site

A novel series of shikonin-benzo[b]furan derivatives were designed and synthesized as tubulin polymerization inhibitors, and their biological activities were evaluated. Most compounds revealed the comparable anti-proliferation activities against the cancer cell lines to that of shikonin and simultaneously low cytotoxicity to non-cancer cells. Among them, compound 6c displayed powerful anti-cancer activity with the IC50 value of 0.18 μM against HT29 cells, which was significantly better than that of the reference drugs shikonin and CA-4. What's more, 6c could inhibit tubulin polymerization and compete with [3H] colchicine in binding to tubulin. Further biological studies depicted that 6c can induce cell apoptosis and cell mitochondria depolarize, regulate the expression of apoptosis related proteins in HT29 cells. Besides, 6c actuated the HT29 cell cycle arrest at G2/M phase, and influenced the expression of the cell-cycle related protein. Moreover, 6c displayed potent inhibition on cell migration and tube formation that contributes to the antiangiogenesis. These results prompt us to consider 6c as a potential tubulin polymerization inhibitor and is worthy for further study.

Tandem Synthesis of 2-Carboxybenzofurans via Sequential Cu-Catalyzed C-O Coupling and Mo(CO)6-Mediated Carbonylation Reactions

A modular tandem synthesis of 2-carboxybenzofurans from 2-gem-dibromovinylphenols has been established based on a sequence of Cu-catalyzed intramolecular C-O coupling and Mo(CO)6-mediated intermolecular carbonylation reactions. This protocol allowed one-step access to a broad variety of functionalized benzofuran-2-carboxylic acids, esters, and amides in good to excellent yields under Pd- and CO gas-free conditions.

Synthesis and AChE inhibitory activity of N-glycosyl benzofuran derivatives

Six N-glycosyl benzofuran derivatives were synthesized by the catalysis of organic bases and condensation agents. The benzofuran derivatives were obtained by the reaction of various salicylaldehydes in acetone, and then hydrolyzed to the corresponding carboxylic acids. Finally, the target compounds were synthesized by acylation and the reaction conditions were optimized. The acetylcholinesterase (AChE) inhibitory activity of the desired compounds was tested using Ellman's method. Most of the compounds showed acetylcholinesterase-inhibition activity; N-(2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)benzofuran-2-carbxamide (5a) showed the best acetylcholinesterase inhibition, with an inhibitory rate of 84%.

Benzocarbazoles five-membered unsaturated heterocyclic compound or its pharmaceutically acceptable salts and its preparation method, pharmaceutical composition and its application

Provided in the present invention are an unsaturated 5-membered benzo-heterocyclic compound with the structure as shown in general formula I or pharmaceutical salts thereof, and a preparation method, a pharmaceutical composition and the use thereof. Experiments have shown that the compound of the present invention has the effects of upregulating the expression activity of bone morphogenetic protein BMP-2 and anti-osteoporosis in vivo, and also has the effect of improving SAMP6 mice osteoporosis symptoms. Activity tests in vitro have shown that the compound of the present invention shows an obvious upregulation effect on bone morphogenetic protein BMP-2.

Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats

The BMP pathway is a promising new target for the design of therapeutic agents for the treatment of low bone mass. To enrich our understanding of SAR and based on our previously concluded structure-effect relationship, 23 derivatives were prepared in this

IRE-1α INHIBITORS

PROBLEM TO BE SOLVED: To provide compounds which directly inhibit inositol requiring enzyme 1 (IRE-1α activity) in vitro, prodrugs, and pharmaceutically acceptable salts thereof. SOLUTION: The present invention provides a compound represented by formula (A) [R3 and R4 are H or the like; Q5-Q8, together with the benzene ring to which they are attached, form a benzofused ring, where at least one of Q5-Q8 is a heteroatom selected from N, O, and S. COPYRIGHT: (C)2016,JPOandINPIT

STYRYLBENZOFURAN DERIVATIVES AS INHIBITORS FOR BETA-AMYLOID FIBRIL FORMATION AND PREPARATION METHOD THEREOF

The present invention relates to a novel compound which efficiently inhibits the formation of beta-amyloid fibrils in the brain to be useful for preventing or treating a degenerative brain disease, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient.

Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-Regulators: Synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized

In this work, substituted benzothiophene and benzofuran compounds were found to be a new class of potential anabolic agents by enhancing BMP-2 expression. A series of benzothiophene and benzofuran derivatives have been synthesized, and their activities of